First Hawaiian Bank Sells 1,509 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

First Hawaiian Bank trimmed its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 10.9% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 12,295 shares of the medical research company’s stock after selling 1,509 shares during the quarter. First Hawaiian Bank’s holdings in Charles River Laboratories International were worth $2,540,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of CRL. Norges Bank purchased a new stake in shares of Charles River Laboratories International during the fourth quarter valued at $101,319,000. Point72 Asset Management L.P. increased its stake in shares of Charles River Laboratories International by 499.1% during the fourth quarter. Point72 Asset Management L.P. now owns 368,984 shares of the medical research company’s stock worth $87,228,000 after purchasing an additional 307,398 shares in the last quarter. Meritage Group LP grew its stake in Charles River Laboratories International by 30.8% during the 4th quarter. Meritage Group LP now owns 1,155,376 shares of the medical research company’s stock valued at $273,131,000 after acquiring an additional 271,743 shares in the last quarter. Epoch Investment Partners Inc. grew its stake in Charles River Laboratories International by 2,733.4% during the 1st quarter. Epoch Investment Partners Inc. now owns 247,501 shares of the medical research company’s stock valued at $67,060,000 after acquiring an additional 238,766 shares in the last quarter. Finally, KBC Group NV grew its stake in shares of Charles River Laboratories International by 5,003.9% in the 4th quarter. KBC Group NV now owns 215,639 shares of the medical research company’s stock valued at $50,977,000 after buying an additional 211,414 shares during the period. 98.91% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Charles River Laboratories International

In other news, EVP Joseph W. Laplume sold 1,304 shares of the business’s stock in a transaction dated Friday, May 10th. The shares were sold at an average price of $226.97, for a total value of $295,968.88. Following the sale, the executive vice president now directly owns 23,276 shares in the company, valued at approximately $5,282,953.72. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 1.30% of the company’s stock.

Charles River Laboratories International Trading Down 3.1 %

Shares of Charles River Laboratories International stock traded down $7.20 during trading on Monday, reaching $226.40. 628,505 shares of the stock were exchanged, compared to its average volume of 542,673. The company has a quick ratio of 1.37, a current ratio of 1.75 and a debt-to-equity ratio of 0.73. Charles River Laboratories International, Inc. has a 1 year low of $161.65 and a 1 year high of $275.00. The stock’s fifty day moving average is $215.07 and its 200 day moving average is $231.43. The firm has a market cap of $11.66 billion, a price-to-earnings ratio of 26.65, a price-to-earnings-growth ratio of 2.32 and a beta of 1.38.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Thursday, May 9th. The medical research company reported $2.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.05 by $0.22. The firm had revenue of $1.01 billion during the quarter, compared to analyst estimates of $997.24 million. Charles River Laboratories International had a net margin of 10.81% and a return on equity of 15.16%. As a group, equities research analysts expect that Charles River Laboratories International, Inc. will post 10.99 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

CRL has been the topic of several recent analyst reports. Argus restated a “hold” rating on shares of Charles River Laboratories International in a report on Friday, June 28th. TD Cowen dropped their price objective on Charles River Laboratories International from $260.00 to $228.00 and set a “hold” rating for the company in a report on Monday, May 13th. Mizuho assumed coverage on Charles River Laboratories International in a research note on Friday, June 7th. They set a “neutral” rating and a $235.00 target price for the company. Robert W. Baird decreased their price target on Charles River Laboratories International from $271.00 to $239.00 and set an “outperform” rating for the company in a research note on Wednesday, July 10th. Finally, StockNews.com cut Charles River Laboratories International from a “buy” rating to a “hold” rating in a research note on Friday, June 14th. Eight research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $252.29.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).